Information
282 Hagui-ro, Dongan-gu, Anyang, Gyeonggi-do, South Korea
+82 31-337-5147
-
-
Overview
- Summary
- Kukjeon Pharmaceutical is a chemical total solution company leveraging 50 years of expertise in active pharmaceutical ingredients (APIs) and electronic materials. The company supplies raw materials to domestic and international pharmaceutical and electronic material companies, contributing to new drug development and the localization of advanced materials.Kukjeon Pharmaceutical is a chemical total solution company leveraging 50 years of expertise in active pharmaceutical ingredients (APIs) and electronic materials. The company supplies raw materials to domestic and international pharmaceutical and electronic material companies, contributing to new drug development and the localization of advanced materials.
- Key Products/Technologies
- Active Pharmaceutical Ingredients (APIs): Handling approximately 353 types of APIs. Production of various APIs for chronic diseases, including Ezetimibe, Spherical Adsorbent Carbon, and Altioc Acid Tromethamine Salt. Possession of GMP-compliant manufacturing facilities and systematic quality control systems.Active Pharmaceutical Ingredients (APIs): Handling approximately 353 types of APIs. Production of various APIs for chronic diseases, including Ezetimibe, Spherical Adsorbent Carbon, and Altioc Acid Tromethamine Salt. Possession of GMP-compliant manufacturing facilities and systematic quality control systems.
- Electronic Materials: Development and mass production of OLED intermediates and products, such as Quantum Dot (QD) OLED augmented reality (AR) film materials and foldable materials. Development and commercialization of secondary battery electrolyte additives, including low-resistance electrolyte additives. Supply of semiconductor solvents, additives, and core materials for HBM (High Bandwidth Memory) packaging process special cleaning solutions, with localization and integration into mass production lines. Establishment of high-purity synthesis technology, automated facilities, and specialized reaction equipment like Hastelloy reactors, polymer reactors, and TCU systems.Electronic Materials: Development and mass production of OLED intermediates and products, such as Quantum Dot (QD) OLED augmented reality (AR) film materials and foldable materials. Development and commercialization of secondary battery electrolyte additives, including low-resistance electrolyte additives. Supply of semiconductor solvents, additives, and core materials for HBM (High Bandwidth Memory) packaging process special cleaning solutions, with localization and integration into mass production lines. Establishment of high-purity synthesis technology, automated facilities, and specialized reaction equipment like Hastelloy reactors, polymer reactors, and TCU systems.
- New Drug Development: Oral Alzheimer's treatment (NuCerin, HY-209) in clinical phase 1. Atopic dermatitis treatment (NuGel) and COVID-19/pneumonia treatment (NuSepin) in clinical phase 2. Expansion of new drug pipelines through collaborations with companies like Shaperoon and TH Pharm.New Drug Development: Oral Alzheimer's treatment (NuCerin, HY-209) in clinical phase 1. Atopic dermatitis treatment (NuGel) and COVID-19/pneumonia treatment (NuSepin) in clinical phase 2. Expansion of new drug pipelines through collaborations with companies like Shaperoon and TH Pharm.
- Core Advantages
- Possession of 50 years of accumulated expertise in API business and organic chemistry technology. This forms the foundation for building a broad network of domestic and international API manufacturers and chemical companies.Possession of 50 years of accumulated expertise in API business and organic chemistry technology. This forms the foundation for building a broad network of domestic and international API manufacturers and chemical companies.
- Extensive customer network supplying raw materials to approximately 200 domestic and international pharmaceutical and electronic material companies. Expertise in APIs supporting the successful completion of client's finished product businesses.Extensive customer network supplying raw materials to approximately 200 domestic and international pharmaceutical and electronic material companies. Expertise in APIs supporting the successful completion of client's finished product businesses.
- Acquisition and maintenance of GMP (Good Manufacturing Practice) certificates, ISO 9001 certification, and Japanese PMDA compliance and foreign manufacturer certification. A high-level GMP quality control system operating over 40 physicochemical and microbiological analysis instruments, including GC-MS/MS and LC-MS/MS.Acquisition and maintenance of GMP (Good Manufacturing Practice) certificates, ISO 9001 certification, and Japanese PMDA compliance and foreign manufacturer certification. A high-level GMP quality control system operating over 40 physicochemical and microbiological analysis instruments, including GC-MS/MS and LC-MS/MS.
- High-purity synthesis and purification technology in the electronic materials sector. The ultra-high purity purification technology for HBM process materials meets the stringent quality standards of global semiconductor companies.High-purity synthesis and purification technology in the electronic materials sector. The ultra-high purity purification technology for HBM process materials meets the stringent quality standards of global semiconductor companies.
- Strategy of diversifying business portfolio into electronic materials and new drug development, based on the stable cash cow of the API business. This aims to achieve a sales target of 200 billion KRW by 2027.Strategy of diversifying business portfolio into electronic materials and new drug development, based on the stable cash cow of the API business. This aims to achieve a sales target of 200 billion KRW by 2027.
- Contribution to reducing supply chain risks and enhancing competitiveness in domestic industries through the localization of specialized materials for high-value-added sectors like advanced semiconductors and displays. Capability to provide molecular design and technical support through joint research with clients, achieving high economic efficiency.Contribution to reducing supply chain risks and enhancing competitiveness in domestic industries through the localization of specialized materials for high-value-added sectors like advanced semiconductors and displays. Capability to provide molecular design and technical support through joint research with clients, achieving high economic efficiency.
- Target Industrie
- Pharmaceutical Industry: Contribution to the finished pharmaceutical product market through API supply and new drug development.Pharmaceutical Industry: Contribution to the finished pharmaceutical product market through API supply and new drug development.
- Electronics Industry: Supply of advanced electronic materials for displays (OLED, QD-OLED, foldable), semiconductors (AI semiconductor processes, HBM), and secondary batteries (electrolyte additives).Electronics Industry: Supply of advanced electronic materials for displays (OLED, QD-OLED, foldable), semiconductors (AI semiconductor processes, HBM), and secondary batteries (electrolyte additives).
- Fine Chemical Industry: Provision of various chemical-based products and services, with capabilities in manufacturing high-functional fine chemical products.Fine Chemical Industry: Provision of various chemical-based products and services, with capabilities in manufacturing high-functional fine chemical products.
- Major Markets
- South Korea, Southeast Asia, IndiaSouth Korea, Southeast Asia, India
- EuropeEurope
- North AmericaNorth America
- BrazilBrazil
- Certifications/Patents
- GMP (Good Manufacturing Practice) Certificate of Conformity (for APIs).GMP (Good Manufacturing Practice) Certificate of Conformity (for APIs).
- ISO 9001 certification (obtained in 2010).ISO 9001 certification (obtained in 2010).
- Japanese PMDA compliance (2016) and Japanese foreign manufacturer certification (2014).Japanese PMDA compliance (2016) and Japanese foreign manufacturer certification (2014).
- Key Patents: Manufacturing method of Itopride and intermediate compounds (Patent No. 1153713), Pharmaceutical composition containing Orlistat and its manufacturing method (Patent No. 0958197), Manufacturing method of Ethyl-4-methyl-5-thiazolecarboxylate (Patent No. 1723832), Manufacturing method of Agomelatine (Patent No. 1606395), Manufacturing method of Pramipexole (Patent No. 1546713).Key Patents: Manufacturing method of Itopride and intermediate compounds (Patent No. 1153713), Pharmaceutical composition containing Orlistat and its manufacturing method (Patent No. 0958197), Manufacturing method of Ethyl-4-methyl-5-thiazolecarboxylate (Patent No. 1723832), Manufacturing method of Agomelatine (Patent No. 1606395), Manufacturing method of Pramipexole (Patent No. 1546713).
- Numerous awards including Technology Innovation Management Award, Trade Promotion Merit Award, Three Million Dollar Export Tower, and Ten Million Dollar Export Tower.Numerous awards including Technology Innovation Management Award, Trade Promotion Merit Award, Three Million Dollar Export Tower, and Ten Million Dollar Export Tower.
Introduction
Location
282 Hagui-ro, Dongan-gu, Anyang, Gyeonggi-do, South Korea
클릭하여 위치 살펴보기
